Literature DB >> 20856627

Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study.

Howard J Lim1, Sharlene Gill, Caroline Speers, Barbara Melosky, Jeff Barnett, Catherine Fitzgerald, Susan O'Reilly, Hagen Kennecke.   

Abstract

A look at the temporal impact of advancements in therapeutic options in the last 10 years-from fluorouracil to irinotecan and oxaliplatin-on overall survival in a population-based cohort.

Entities:  

Year:  2009        PMID： 20856627      PMCID： PMC2795424          DOI： 10.1200/JOP.0942001

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  10 in total

1.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

Review 2.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

Authors:  M A Poon; M J O'Connell; C G Moertel; H S Wieand; S A Cullinan; L K Everson; J E Krook; J A Mailliard; J A Laurie; L K Tschetter
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

3.  Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.

Authors:  E Jäger; M Heike; H Bernhard; O Klein; G Bernhard; D Lautz; J Michaelis; K H Meyer zum Büschenfelde; A Knuth
Journal:  J Clin Oncol       Date:  1996-08       Impact factor: 44.544

4.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

5.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

6.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

7.  Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

Authors:  Axel Grothey; Daniel Sargent; Richard M Goldberg; Hans-Joachim Schmoll
Journal:  J Clin Oncol       Date:  2004-04-01       Impact factor: 44.544

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Trends in chemotherapy utilization for colorectal cancer.

Authors:  Daniel Renouf; Hagen Kennecke; Sharlene Gill
Journal:  Clin Colorectal Cancer       Date:  2008-11       Impact factor: 4.481

10.  Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.

Authors:  T R Buroker; M J O'Connell; H S Wieand; J E Krook; J B Gerstner; J A Mailliard; P L Schaefer; R Levitt; C G Kardinal; D H Gesme
Journal:  J Clin Oncol       Date:  1994-01       Impact factor: 44.544
  10 in total
  5 in total

1.  Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.

Authors:  Martha M Kirstein; Ansgar Lange; Anne Prenzler; Michael P Manns; Stefan Kubicka; Arndt Vogel
Journal:  Oncologist       Date:  2014-10-17

2.  A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer.

Authors:  Guan-Li Su; Yuan-Yuan Wang; Jin-Cheng Wang; Hao Liu
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

Review 3.  First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials.

Authors:  Arndt Vogel; Martha M Kirstein
Journal:  Innov Surg Sci       Date:  2018-05-07

Review 4.  TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer.

Authors:  Cheng-Jiang Liu; Ting Hu; Ping Shao; Wu-Yang Chu; Yu Cao; Feng Zhang
Journal:  Gastroenterol Res Pract       Date:  2021-12-20       Impact factor: 2.260

5.  Treatment patterns for metastatic colorectal cancer in Spain.

Authors:  E Aranda; E Polo; C Camps; A Carrato; E Díaz-Rubio; V Guillem; R López; A Antón
Journal:  Clin Transl Oncol       Date:  2020-01-23       Impact factor: 3.405
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.